Seeking Clues to Teva Pharmaceutical Industries (TEVA) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics

Core Viewpoint - Teva Pharmaceutical Industries Ltd. is expected to report quarterly earnings of $0.68 per share, reflecting a year-over-year decline of 1.5%, with revenues projected at $4.35 billion, an increase of 0.4% from the previous year [1]. Earnings Estimates - Over the last 30 days, the consensus EPS estimate has been revised upward by 0.4%, indicating analysts' reassessment of their initial forecasts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock performance [3]. Revenue Estimates - The consensus estimate for 'Revenue- COPAXONE- Total' is $92.90 million, indicating a year-over-year decline of 31.2% [5]. - 'Revenue- API sales to third parties' is expected to reach $131.42 million, reflecting a year-over-year increase of 1.1% [5]. - 'Revenue- Other- Total' is projected at $165.39 million, showing a significant year-over-year increase of 62.2% [5]. Geographic Revenue Estimates - 'Geographic Revenue- Europe' is expected to be $1.30 billion, up 2.7% from the previous year [6]. - 'Geographic Revenue- International Markets' is forecasted at $592.56 million, indicating a decline of 3.3% year-over-year [6]. - 'Geographic Revenue- United States' is projected to reach $2.25 billion, reflecting a year-over-year increase of 1.1% [6]. Specific Product Revenue Estimates - 'Geographic Revenue- United States- Anda' is expected to be $371.57 million, down 2.2% year-over-year [7]. - 'Geographic Revenue- Europe- COPAXONE' is projected at $40.26 million, indicating a decline of 24.1% from the previous year [7]. - 'Geographic Revenue- International Markets- Generic products' is expected to be $460.92 million, down 3.4% year-over-year [8]. Stock Performance - Teva Pharmaceutical Industries shares have increased by 2.8% over the past month, outperforming the Zacks S&P 500 composite, which rose by 2.1% [9]. - With a Zacks Rank 2 (Buy), Teva is expected to outperform the overall market performance in the near term [10].